Agios Gordios Beach Guide: Visiting The Corfu Coastline
Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science is foundational to. Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming events and other. At Agios, we are studying how PK activation could potentially benefit people with SCD. PK activation modulates 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs which reduces hemoglobin S. Nov 19, 2025 · Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X. “In 2025, Agios delivered another year of strong and consistent execution across our portfolio, marking meaningful progress toward our goal of becoming a sustainable and diversified rare disease.
Agios offers the myAgios ® patient support services program as a single point of engagement for eligible patients, including access support, prescription fulfillment, financial assistance, disease education. Find out what Agios is all about on this virtual tour of our space, led by sickle cell disease warrior DeMitrious Wyant. We’re proud to be a place where science meets heart, and meaningful. Nov 3, 2025 · Agios is presenting new preclinical and clinical data on mitapivat, the company’s first-in-class pyruvate kinase (PK) activator, along with research from two Agios-supported advisory councils. Jan 13, 2025 · In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website.
Agios Gordios beach | Stablo Residence
